Myelitis News and Research

RSS

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Cases of Acute Flaccid Myelitis on the rise across U.S.

According to the Centre for Disease Prevention and Control (CDC), cases of dangerous and rare Acute Flaccid Myelitis (AFM) are being noted across United States. This disease manifests similar to acute flaccid paralysis caused by polio virus say the experts. There is at present no treatment for this condition that primarily affects children and leads to paralysis of the limbs.

18 Oct 2018

Mysterious polio-like illness baffles medical experts while frightening parents

A spike in the number of children with a rare neurological disease that causes polio-like symptoms has health officials across the country scrambling to understand the illness. Yet, more than four years after health officials first recorded the most recent uptick in cases, much about the national outbreak remains a mystery.

17 Oct 2018

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

UT Southwestern scientists identify gene mutation linked with perplexing brain condition

Scientists conducting one of the largest full DNA analyses of a rare disease have identified a gene mutation associated with a perplexing brain condition that blinds and paralyzes patients.

20 Jun 2018

Popular allergy drug may reduce relapses in patients with neuromyelitis optica

The addition of cetirizine (the popular allergy medication sold under the brand name Zyrtec) to standard therapy is safe, well-tolerated, and may reduce relapses in patients with neuromyelitis optica (NMO), a rare and severe disease that causes inflammation and demyelination (damage to the myelin - the protective coating of nerve cells), primarily in the optic nerve (optic neuritis), spinal cord (myelitis), and brainstem.

2 Feb 2018

Researchers identify virus as likely cause of mystery polio-like paralysis

A major review by UNSW Sydney medical researchers has identified strong evidence that a virus called Enterovirus D68 is the cause of a mystery polio-like illness that has paralysed children in the US, Canada and Europe.

22 Jan 2018

Mayo Clinic launches new clinical test that distinguishes IDDs from multiple sclerosis

Mayo Clinic has launched a first-in-the-U.S. clinical test that will help patients who recently have been diagnosed with an inflammatory demyelinating disease (IDD) but may be unsure of the exact disorder.

28 Nov 2017

Severe cases of polio-like illness observed among children in many countries

In Germany in the summer and autumn of 2016, several cases of illness in children were observed that were accompanied by acute flaccid paralysis.

8 Sep 2017

Breakthrough brain repair discovery could revolutionise treatment of Multiple Sclerosis

Queen's University Belfast scientists have discovered that specific cells from the immune system are key players in brain repair - a fundamental breakthrough that could revolutionise the treatment of debilitating neurological disorders such as Multiple Sclerosis.

15 Mar 2017

UC San Diego researchers receive CIRM grants to advance studies on Zika virus and cancer

The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine has approved a pair of $2 million awards to University of California San Diego School of Medicine researchers to advance studies of new treatments for Zika virus infections and the use of stem cell-derived natural killer (NK) cells to target ovarian cancer and other malignancies.

20 Jan 2017

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.

7 Nov 2016

Scientists report new neurological complication from Zika virus infection

Dr. John England, Professor and Chair of Neurology at LSU Health New Orleans School of Medicine, and colleagues in Honduras and Venezuela have reported a new neurological complication of infection with the Zika virus.

26 Aug 2016

Researchers link sensory polyneuropathy with acute Zika virus infection

A group of researchers from Honduras, Venezuela and the USA has described the first case of sensory polyneuropathy associated with acute Zika virus infection.

26 Aug 2016

Experts at EAN Congress discuss spread of Zika virus threat across Europe

The Zika epidemic has long assumed global proportions, experts told the Congress of the European Academy of Neurology in Copenhagen. Europe needs to get prepared to deal with the relentless spread of the health threat, in particular with a view to "imported" infection.

31 May 2016

More neurological resources needed to manage Zika virus infections

WFN Zika-Info-Service: World Federation of Neurology establishes Work Group on Zika virus to support international efforts - Lack of neurological resources in countries most concerned by the virus.

28 Apr 2016

Researchers report first case of acute myelitis due to Zika virus infection

A first case of acute myelitis following infection with Zika virus has been reported for the first time by a research team from Inserm Unit 1127 Brain and Spinal Cord Institute (Inserm/CNRS/Sorbonne University) and neurologists at Pointe-à-Pitre University Hospital and the University of the Antilles.

9 Mar 2016